A Brief History of Ketamine's FDA Approval
Ketamine was first synthesized in 1962 by Calvin Stevens at Parke-Davis Laboratories. It was developed as a safer alternative to phencyclidine (PCP), which had been used as an anesthetic but caused severe and prolonged emergence reactions. Ketamine retained the dissociative anesthetic properties while producing shorter-lasting and more manageable side effects. For a broader historical perspective, see our history of ketamine tablets article.
The U.S. Food and Drug Administration (FDA) approved ketamine hydrochloride as an injectable anesthetic in 1970 under the brand name Ketalar. This approval covered its use for induction and maintenance of general anesthesia, particularly in situations requiring anesthesia without the need for muscle relaxation.
For over five decades, ketamine has remained on the World Health Organization's List of Essential Medicines as a core anesthetic agent. Its safety profile in surgical settings is extensively documented, with millions of doses administered worldwide each year.
What Does FDA Approval Actually Mean?
FDA approval means that a pharmaceutical company has submitted a New Drug Application (NDA) demonstrating, through rigorous clinical trials, that a specific drug formulation is safe and effective for a specific indication (medical use) at specific doses in a specific patient population.
Key points about FDA approval:
- It is indication-specific: A drug can be approved for one condition and not another, even if evidence supports its use in the unapproved condition
- It is formulation-specific: Approval of an injectable form does not extend to a tablet form, and vice versa
- It is not the only legal pathway for prescribing: Licensed physicians can prescribe approved drugs for non-approved (off-label) uses based on their clinical judgment
Ketamine's FDA approval covers injectable formulations for anesthesia. It does not currently cover oral tablet formulations, nor does it cover the treatment of depression, chronic pain, or other conditions for which ketamine is increasingly prescribed.
Off-Label Prescribing: What Patients Should Know
When your clinician prescribes a ketamine tablet for depression or pain, they are engaging in "off-label" prescribing. This term can sound concerning to patients who are unfamiliar with how common and well-established this practice is.
Off-Label Use Is Extremely Common
The FDA itself acknowledges that off-label prescribing is a fundamental part of medical practice. Studies estimate that approximately 20% of all prescriptions in the United States are written for off-label uses. In certain specialties, the rate is even higher:
- Oncology: Many cancer chemotherapy regimens include off-label drug uses
- Pediatrics: The majority of medications used in children are prescribed off-label because clinical trials often exclude pediatric populations
- Psychiatry: Several widely used psychiatric medications are frequently prescribed off-label
The Legal and Ethical Framework
Off-label prescribing is legal when performed by a licensed physician exercising informed clinical judgment. The key requirements are:
- Scientific basis: The prescriber should have a reasonable scientific rationale, typically supported by published research
- Informed consent: The patient should be informed that the use is off-label and understand the evidence supporting it
- Standard of care: The prescribing decision should align with accepted medical practice within the relevant specialty
For ketamine in depression, the scientific basis is substantial. Hundreds of peer-reviewed studies, including randomized controlled trials, have demonstrated ketamine's rapid antidepressant effects. Major academic medical centers and psychiatric organizations recognize ketamine as a treatment option for treatment-resistant depression.
Ketamine Tablet Names and Formulations
Patients searching for "ketamine tablet name" often want to know the specific product they might receive. Currently, ketamine tablets are primarily available through two channels:
Compounded Ketamine Tablets
The majority of ketamine tablets prescribed for depression or pain are compounded by specialty pharmacies. These are prepared using pharmaceutical-grade ketamine hydrochloride powder, which is combined with excipients and compressed into tablet form. Compounded tablets do not have a brand name; they are labeled simply as "ketamine hydrochloride" with the dose and the compounding pharmacy's information.
Common compounded tablet doses include 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, though pharmacies can prepare virtually any dose as prescribed.
Ketalar (Injectable, Brand Name)
Ketalar is the original FDA-approved brand name for injectable ketamine hydrochloride. It is used in hospital and clinical settings for anesthesia. Ketalar is not a tablet and is not prescribed for at-home use.
Investigational Oral Formulations
Several pharmaceutical companies have developed proprietary oral ketamine formulations that are in various stages of clinical trials seeking FDA approval for depression. These products have their own development-stage names and, if approved, will receive brand names at that time.
Esketamine (Spravato): The FDA-Approved Relative
In March 2019, the FDA approved esketamine nasal spray under the brand name Spravato for treatment-resistant depression in adults, with a subsequent approval in 2020 for major depressive disorder with acute suicidal ideation or behavior. This was a landmark decision, as it was the first ketamine-related product approved specifically for a psychiatric indication.
How Esketamine Differs from Ketamine
Ketamine exists as two mirror-image molecules (enantiomers): S-ketamine (esketamine) and R-ketamine (arketamine). Standard ketamine is a racemic mixture containing equal parts of both enantiomers. Esketamine is the isolated S-enantiomer.
Important distinctions between Spravato and ketamine tablets:
- Spravato is a nasal spray, not a tablet
- Spravato requires in-clinic administration with a mandatory 2-hour observation period due to its Risk Evaluation and Mitigation Strategy (REMS)
- Spravato uses only the S-enantiomer, while ketamine tablets contain the racemic mixture
- Spravato has a specific FDA-approved indication for treatment-resistant depression
- Cost differs significantly: Spravato's list price and insurance requirements differ from compounded ketamine tablets
The existence of Spravato's FDA approval does not make ketamine tablets illegal or inappropriate. They are different products used in different clinical contexts, and many patients and clinicians prefer the flexibility and accessibility of sublingual ketamine tablet therapy.
The Path Toward FDA Approval for Oral Ketamine
Multiple pharmaceutical companies are actively pursuing FDA approval for oral ketamine formulations targeting depression. This process involves:
Phase I Trials
Safety and pharmacokinetic studies in healthy volunteers and small patient groups to establish safe dosing ranges and absorption characteristics.
Phase II Trials
Efficacy studies in patients with the target condition (typically treatment-resistant depression) to determine optimal doses and gather preliminary evidence of effectiveness.
Phase III Trials
Large, randomized, placebo-controlled trials designed to definitively demonstrate that the drug is safe and effective for the intended indication. These trials are the primary basis for FDA approval decisions.
New Drug Application (NDA)
After successful Phase III trials, the company submits an NDA containing all clinical data, manufacturing information, and proposed labeling for FDA review.
This process typically takes 7 to 15 years and costs hundreds of millions of dollars. The fact that ketamine is a generic drug creates a unique economic challenge: companies must develop novel formulations with patent protection to justify the investment in clinical trials.
What FDA Approval Would Change
If an oral ketamine tablet receives FDA approval for depression, several practical changes would follow:
- Insurance coverage: FDA-approved drugs are more likely to be covered by insurance plans
- Standardized protocols: The approval would establish specific dosing guidelines, administration requirements, and monitoring standards
- Prescribing accessibility: More clinicians might feel comfortable prescribing an FDA-approved product than an off-label compounded one
- Post-market surveillance: The manufacturer would be required to monitor and report adverse events systematically
However, FDA approval would not necessarily mean the end of compounded ketamine tablets. Compounding pharmacies serve an important role in providing customized doses and formulations that manufactured products may not offer.
Safety Monitoring Without FDA-Specific Oversight
In the absence of a specific FDA approval for oral ketamine tablets in depression, how is patient safety maintained?
Clinical Practice Guidelines
Professional organizations including the American Psychiatric Association and the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) have developed clinical guidelines for ketamine therapy. These guidelines address patient selection, dosing, monitoring, and contraindications.
Prescriber Qualifications
Clinicians who prescribe ketamine for depression are typically psychiatrists, anesthesiologists, or other physicians with specialized training in ketamine therapy. Many have completed continuing medical education programs focused specifically on ketamine prescribing.
State Medical Board Oversight
State medical boards retain authority to investigate and discipline physicians whose prescribing practices fall below the standard of care, regardless of whether a drug is used on-label or off-label.
Patient Monitoring Protocols
Responsible ketamine therapy programs include structured monitoring: regular check-ins, standardized depression rating scales, vital sign monitoring, and clear protocols for dose adjustments and discontinuation.
Making Informed Decisions
Understanding ketamine's regulatory status helps you evaluate your treatment with appropriate context. Key questions to discuss with your clinician:
- What is the evidence supporting ketamine tablets for my specific condition?
- How does your practice monitor safety during treatment?
- What clinical guidelines do you follow for dosing and administration?
- How will we measure whether the treatment is working?
- What are the criteria for continuing, adjusting, or discontinuing treatment?
The regulatory landscape for ketamine is evolving. Staying informed through reliable sources, including your treatment team, helps you navigate your care with confidence.
References
- FDA Approval of Ketamine (Ketalar) — Original NDA — FDA prescribing information for Ketalar (injectable ketamine)
- FDA Approval of Spravato (Esketamine) — FDA press announcement on Spravato approval for treatment-resistant depression
- Off-Label Drug Use: An FDA Regulatory Term — Analysis of the legal and regulatory framework for off-label prescribing
- WHO Model List of Essential Medicines — World Health Organization essential medicines list including ketamine
- Rapid-Acting Antidepressant Effects of Ketamine: A Review — Comprehensive review of the evidence for ketamine's antidepressant properties
- NIH NIMH — Research on Ketamine for Depression — National Institute of Mental Health coverage of ketamine depression research
Share